Business
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients
PORTICO-2 designed to validate vafidemstat’s efficacy in reducing aggression in BPD patientsPrimary endpoint: STAXI-2 Trait Anger (patient-reported)Key secondary endpoint: Overt Aggression Scale-Modified (OAS-M) (clinician-rated)Additional secondary endpoints will assess global clinical improvementProtocol finalized following FDA guidance and input from leading US psychiatry expertsUpcoming KOL webinar to discuss trial design and the urgent medical need in BPD MADRID and CAMBRIDGE, Mass., June 2
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"PORTICO-2 designed to validate vafidemstat’s efficacy in reducing aggression in BPD patients","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Primary endpoint: STAXI-2 Trait Anger (patient-reported)","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Key secondary endpoint: Overt Aggression Scale-Modified (OAS-M) (clinician-rated)","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional secondary endpoints will assess global clinical improvement","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Protocol finalized following FDA guidance and input from leading US psychiatry experts","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Upcoming KOL webinar to discuss trial design and the urgent medical need in BPD","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":464,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it has submitted the clinical trial protocol for its Phase III PORTICO-2 trial to the U.S. Food and Drug Administration (FDA) to initiate a registrational trial to evaluate vafidemstat in patients with Borderline Personality Disorder (BPD). The PORTICO-2 trial builds upon the encouraging results observed in the previous PORTICO Phase IIb study, where vafidemstat demonstrated significant and clinically meaningful reductions in secondary endpoints measuring aggression and overall BPD improvement. Aggression is a key symptom domain in BPD that currently represents a major unmet medical need and will be the primary endpoint in PORTICO-2. Vafidemstat, an orally active LSD1...